Noxopharm Appoints New CEO to Advance Sofra Platform and Growth Strategy
Noxopharm Limited (ASX: NOX) has reported the appointment of Dr Olivier Laczka as Chief Executive Officer, marking a strategic leadership transition as the Company advances its clinical-stage programs. Dr Laczka, previously Chief Scientific Officer – Inflammation, has played a central role in the development of the Company’s Sofra™ technology platform and brings extensive experience across drug development, biotechnology and diagnostics. His appointment supports leadership continuity and is consistent with the Company’s emphasis on advancing new opportunities across its development pipeline. The transition follows recent clinical and research milestones, including outcomes from the HERACLES trial and publication of key scientific findings. Management expects the leadership change to support execution of the next phase of development and commercial strategy. With a strong scientific foundation and established partnerships, Noxopharm is positioned to continue advancing its therapeutic platforms and delivering further clinical progress.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Noxopharm Appoints New CEO to Advance Sofra Platform and Growth Strategy
Noxopharm Limited (ASX: NOX) has reported the appointment of Dr Olivier Laczka as Chief Executive Officer, marking a strategic leadership transition as the Company advances its clinical-stage programs. Dr Laczka, previously Chief Scientific Officer – Inflammation, has played a central role in the development of the Company’s Sofra™ technology platform and brings extensive experience across drug development, biotechnology and diagnostics. His appointment supports leadership continuity and is consistent with the Company’s emphasis on advancing new opportunities across its development pipeline. The transition follows recent clinical and research milestones, including outcomes from the HERACLES trial and publication of key scientific findings. Management expects the leadership change to support execution of the next phase of development and commercial strategy. With a strong scientific foundation and established partnerships, Noxopharm is positioned to continue advancing its therapeutic platforms and delivering further clinical progress.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au